| eplerenone / Generic mfg. |
| Not yet recruiting | 4 | 40 | | | Pfizer Australia and New Zealand, Northern Sydney Local Health District
| Type 1 diabetes | | | | |
2008-001192-29: “Evaluación mediante proteómica de biomarcadores proteicos asociados con el tratamiento con Eplerenona versus espironolactona en pacientes post-infarto agudo de miocardio, diabéticos con hipertensión arterial no controlada y disfunción ventricular sistólica leve”\"Identification of proteomic biomarkers associated with eplerenone treatment versus spironolactone in post-acute coronary syndrome patients, with non-controlled arterial hypertension and ventricular dysfunction\" |
|
|
| Ongoing | 4 | 24 | Europe | INSPRA (eplerenona), ALDACTONE, INSPRA (eplerenona), ALDACTONE (espironolactona), INSPRA (eplerenona), ALDACTONE (espironolactona) | Fundación Investigación y Desarrollo en el Area Cardiovascular | Disfunción ventricular leve-moderada post-infarto agudo de miocardio en pacientes diabéticos con hipertensión arterial no controlada.Low-moderate ventricular dysfunction in post-acute coronary syndrome patients with diabetes and non-controlled arterial hypertension. | | | | |
2013-000189-12: Effects of eplerenone on forearm blood flow De effecten van eplerenone op de bloeddoorstroming in de onderarm |
|
|
| Ongoing | 4 | 14 | Europe | Inspra, Inspra | University Medical Centre Nijmegen, University Medical Centre Nijmegen | healthy volunteers gezonde vrijwilligers | | | | |
2009-011291-29: RACE 3 study: Intensive vs. usual rhythm control for atrial fibrillation. |
|
|
| Ongoing | 4 | 250 | Europe | eplerenone, Spironolactone, atorvastatin, Fluvastatin, Pravastatin, rosuvastatin, Simvastatin, eplerenone, spironolactone, atorvastatin, Fluvastatin, Pravastatin, rosuvastatin, Simvastatin, eplerenone, spironolactone, atorvastatin, Fluvastatin, Pravastatin, rosuvastatin, Simvastatin | Interuniversity Cardiology Institute of the Netherlands (ICIN), Interuniversity Cardiology Institute Netherlands, The Interuniversity Cardiology Institute of the Netherlands (ICIN), Netherlands Heart Foundation (NHS B 2008 035), Working group on Cardiovascular Research, the Netherlands, Sanofi Aventis, Boehringer Ingelheim, Medtronic, Biotronik, St Jude Medical, Boston Scientific, AstraZenenca, Interuniversity Cardiology Institute Netherlands, Working group on Cardiovascular Research, Astra Zeneca, Bayer | atrial fibrillation | | | | |
2018-003662-14: Can patiromer (a substance that binds potassium in the gut) enable use of higher doses of medicines to improve outcomes for people with worsening heart failure? |
|
|
| Not yet recruiting | 4 | 2000 | Europe | Veltassa, Spironolactone, Eplerenone, Not applicable, Powder for oral suspension, Tablet, Veltassa, Spironolactone, Eplerenone | NHS Greater Glasgow and Clyde, University of Glasgow, , VIFOR Pharma | People with heart failure, worsening symptoms and signs of congestion and serum potassium >5mmol/L, People with heart failure, worsening symptoms and signs of congestion and serum potassium >5mmol/L, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-001327-41: Withdrawal of pharmacological treatment in patients responding to cardiac resynchronization therapy: Open and randomized study Retirada de tratamiento farmacologico en pacientes respondedores a terapia de resincronización cardiaca: Estudio abierto y aleatorizado |
|
|
| Ongoing | 4 | 60 | Europe | furosemide, bisoprolol, Coated tablet, Furosemide, Bisoprolol, Eplerenone, Valsartan | Fundación para la formación e investigación sanitarias de la Región de Murcia, ISCarlos III | Heart failure Insuficiencia cardiaca, Heart failure Insuficiencia cardiaca, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ENOVA, NCT04746495: Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation |
|
|
| Withdrawn | 4 | 30 | US | Placebo, Eplerenone 50mg | University of Michigan, National Heart, Lung, and Blood Institute (NHLBI) | Hypertension | 07/23 | 12/23 | | |
| Completed | 4 | 400 | US | Eplerenone vs Amlodipine | Brigham and Women's Hospital | Hypertension, Genetics Hypertension | 08/23 | 01/24 | | |
| Recruiting | 4 | 2500 | Europe | Phase C: Eplerenone, Eplerenone, Phase C: Spironolactone, Spironolactone, Phase C: Torasemide, Torasemide, Phase B: Triplixam / Elestar HCT, Triple Single Pill Combination: Triplixam / Elestar HCT, Phase A: Confirmation of uncontrolled hypertension | National Institute of Cardiology, Warsaw, Poland | Hypertension | 12/25 | 12/25 | | |
NCT05129722: Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial |
|
|
| Recruiting | 4 | 30 | RoW | Low dose combination polydiuretic therapy, Eplerenone (inspra), Bumetanide (Burinex) and Empagliflozin (jardiance), Comparator monotherapy empagliflozin, Empagliflozin, Jardiance | The George Institute, Victor Chang Cardiac Research Institute, St Vincent's Centre for Applied Medical Research | Heart Failure With Preserved Ejection Fraction | 12/23 | 06/24 | | |
NCT06168994: Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease |
|
|
| Not yet recruiting | 4 | 100 | NA | Eplerenone | Assiut University | Paroxysmal Atrial Fibrillation | 09/26 | 05/27 | | |
NCT04519164: Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity |
|
|
| Recruiting | 4 | 80 | US | Eplerenone, Inspra, Chlorthalidone with potassium chloride, hygroton | Brigham and Women's Hospital | Metabolic Syndrome, Hypertension, Overweight and Obesity | 11/25 | 11/25 | | |
NCT03418649: Eplerenone as a Supplement to Epidural Steroid Injections |
|
|
| Withdrawn | 4 | 40 | US | Eplerenone 50 Mg Tab, Inspra, Placebo Oral Tablet, placebo for eplerenone | University of Cincinnati | Degenerative Intervertebral Discs, Sciatic Radiculopathy, Low Back Pain | 12/25 | 06/26 | | |
| Recruiting | 4 | 300 | US | Eplerenone, Amlodipine | Brigham and Women's Hospital | Hypertension, Mineralocorticoid Excess | 02/26 | 06/26 | | |
NCT05030545: Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study |
|
|
| Recruiting | 4 | 40 | US | Eplerenone, Inspra, Mineralocorticoid Receptor Antagonist | Brigham and Women's Hospital | Primary Aldosteronism, Hypertension | 10/26 | 02/27 | | |
NCT05593055: Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension |
|
|
| Recruiting | 4 | 75 | US | Eplerenone, Chlorthalidone, Potassium | Brigham and Women's Hospital | Hypertension, Left Ventricular Hypertrophy | 09/26 | 12/26 | | |
CROWD-ASPECT, NCT03984591: A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure |
|
|
| Enrolling by invitation | 4 | 7200 | Europe | Eplerenone, Spironolactone | Bispebjerg Hospital, Rigshospitalet, Denmark | Systolic Heart Failure | 12/28 | 12/28 | | |
2018-004809-58: Hypertension thErapy with irBesartan Versus epleRenone for Obese hypertensive patients: A Randomized Clinical Trial ΘεÏαπεία Ï…Ï€ÎÏτασης με irBesartan Îναντι epleRenone σε παχÏσαÏκους υπεÏτασικοÏÏ‚ ασθενείς: Μια τυχαίοποιημÎνη κλινική δοκιμή |
|
|
| Ongoing | 3/4 | 340 | Europe | Tablet, Capsule, Coated tablet, Inosamin® 25mg, Lucidel® 150mg, Amlopen® 5mg/cap, Fludex® 1,5 mg | Institute for study, research, education and therapy of vascular, heart, brain and kidney nosologies (I.N.A.K.E.N), Institute for study, research, education and therapy of vascular, heart, brain and kidney nosologies (I.N.A.K.E.N) | Primary Hypertension and Obesity ΥπÎÏταση σε παχÏσαÏκους ασθενείς, Hypertension ΥπÎÏταση, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2010-018639-17: Prospective and open label study with blind end point evaluation on the effect of mineralcorticoid receptor inhibition on endothelial function of the micro- and macrovasculature in patient with metabolic syndrome |
|
|
| Ongoing | 3 | 42 | Europe | Inspra, Inspra | University Hospital Erlangen | Metabolic syndrome | | | | |
2011-005683-21: Effects of the mineralocorticoid-receptor blocker eplerenone on parathyroid hormone levels in patients with parathyroid hormone excess Effekte einer Mineralokortikoidrezeptorblokade mit Eplerenon auf die Parathormonkonzentration in PatientInnen mit einem Parathormonüberschuss |
|
|
| Ongoing | 3 | 110 | Europe | Inspra 25 mg tablets, Inspra 50mg tablets, 0025-1710-01, Inspra 25 mg tablets, Inspra 50mg tablets, Inspra 25 mg tablets, Inspra 50mg tablets | Medizinische Universität Graz, Pfizer | Primary hyperparathyroidism Primärer Hyperparathyreoidismus | | | | |
2015-002168-17: Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensation |
|
|
| Ongoing | 3 | 5890 | Europe, RoW | BAY 94-8862 IR tablet 10 mg, BAY 94-8862 IR tablet 20 mg, Eplerenone 25 mg Film-coated Tablets, Eplerenone 50 mg Film-coated Tablets, BAY 94-8862 coated tablet 10 mg, BAY 94-8862 coated tablet 20 mg, Film-coated tablet, Eplerenone 25 mg Film-coated Tablets, Eplerenone 50 mg Film-coated Tablets | Bayer HealthCare AG, Bayer HealthCare AG | Subjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or both, CHF (reduction of the pumping capacity of the heart), DM type 2 (body's ineffective use of insulin) and CKD (kidneys fail to adequately filter toxins and waste products from the blood), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2017-004641-25: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetic and non diabetic Chronic Kideny Disease Uno studio che prevede la rotazione di piú farmaci che riducono l'albuminuria per valutare quale sia il miglior farmaco per il singolo paziente Estudio para evaluar la acción individal de diferentes clases de fármacos sobre la albuminuria en pacientes diabéticos y no diabéticos con enfermedad renal crónica |
|
|
| Ongoing | 3 | 46 | Europe | Dapaglifozin, Eplerenone, [na], Tablet, Forxiga, Eplerenone | University Medical Center Groningen, UNIVERSITY MEDICAL CENTER GRONINGEN, University Medical Center Groningen | Proteinuric Kidney disease Insufficienza Renale Cronica Proteinurica Enfermedad Renal Crónica Proteinúrica, Reduction in kidney function with increasing in protein in the urine Peggioramento della funzione renale con aumento delle proteine nelle urine Deterioro de la función renal con aumento de la proteinuria en orina, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2016-000113-70`ACTRN12620001004954: The VICI trial - investigating if the steroid Eplerenone can be used in the treatment of fluid build up in the eye caused by Central serous chorio-retinopathy |
|
|
| Completed | 3 | 104 | Europe | Eplerenone, Capsule, Eplerenone 25mg tablets, Eplerenone 50mg tablets | University Hospital Southampton NHS Foundation Trust, NIHR Efficacy and Mechanism Evaluation Programme | Knee osteoarthritis | | | | |
ChiCTR1900028244: The Efficacy and Safety of Eplerenone Tablets in the Treatment of Essential Hypertension (EASTHBP): a Multicenter, Randomized, Double-Blind, Double-Simulation, Positive Drug Parallel-Controlled Trial. |
|
|
| Recruiting | 3 | 284 | | Eplerenone Tablets ;Losarta | The Third Xiangya Hospital of Central South University; The Third Xiangya Hospital of Central South University, Nanjing Cavendish Biological Engineering Technology Co. Ltd. | Hypertension | | | | |
| Active, not recruiting | 3 | 132 | Europe | Eplerenone, Placebo | Central Hospital, Nancy, France | End-stage Renal Disease | 11/21 | 08/31 | | |
EVATRAN, NCT04450953: The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients. |
|
|
| Recruiting | 3 | 36 | Europe | Eplerenone 50mg/day (cross over design), Period without eplerenone (cross over design) | Pr. Nicolas GIRERD | Kidney Transplantation for More Than One Year, Patients With a Kidney Transplantation on Cyclosporine | 03/26 | 03/26 | | |
NCT05198791: Stratified Medicine of Eplerenone in Acute MI/Injury (StratMed-MINOCA) |
|
|
| Recruiting | 2 | 350 | Europe | Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets, Eplerenone, Stratification and standard care | NHS National Waiting Times Centre Board, British Heart Foundation, Abbott | Myocardial Infarction, Acute, Myocardial Infarction With Nonobstructive Coronary Arteries, Myocardial Injury | 07/26 | 07/26 | | |
CSCR, NCT05847049: Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy |
|
|
| Completed | N/A | 16 | RoW | Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy | Dar El Oyoun Hospital | Central Serous Chorioretinopathy | 03/23 | 04/23 | | |
NCT06208072: The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone. |
|
|
| Recruiting | N/A | 50 | Europe | Irbesartan 150mg, I, Eplerenone 25 mg, E | Hippocration General Hospital, National and Kapodistrian University of Athens | Primary Hypertension, Obesity | 12/24 | 02/25 | | |
ESTIA, NCT06117722: TorasEmide Induced Effect on Quality of Life and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone. |
|
|
| Not yet recruiting | N/A | 210 | NA | Eplerenone torasemide in chronic heart failure | Elpen Pharmaceutical Co. Inc. | Chronic Heart Failure | 03/25 | 12/25 | | |
| Not yet recruiting | N/A | 50 | NA | Other, Withdrawal of spironolactone or eplerenone and dapagliflozin or empagliflozin | Imperial College London, Royal Brompton & Harefield NHS Foundation Trust | Heart Failure, Cardiomyopathy, Dilated, Cardiomyopathies, Heart Diseases | 08/26 | 09/26 | | |
UPA-MEST, NCT05797558: Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment |
|
|
| Recruiting | N/A | 80 | Europe | Unilateral adrenalectomy, Surgery, Medical treatment (eplerenone), Mineralocorticoid receptor antagonists | Göteborg University, Karolinska Institutet, Umeå University | Primary Hyperaldosteronism Due to Adrenal Adenoma | 02/27 | 02/27 | | |
| Recruiting | N/A | 80 | | | Dr Andrew Taylor, NHMRC | hypertrophic cardiomyopathy | | | | |